Publication:
Tapentadol withdrawal, a newer trend in opioid overuse in Nepal: A case report

Simple item page
creativeworkseries.issn1812-2027
dc.contributor.authorChand, Hemant
dc.contributor.authorBhatta, Om Prakash
dc.contributor.authorChand, Sabita
dc.contributor.authorDangol, Neha
dc.contributor.authorAwasthi, Sachin
dc.contributor.authorPoudel, Ram Chandra
dc.contributor.authorLamichhane, Ram Prasad
dc.date.accessioned2025-07-13T07:51:33Z
dc.date.available2025-07-13T07:51:33Z
dc.date.issued2025
dc.descriptionHemant Chand Department of Emergency Medicine, Nova Hospital, Nepal Om Prakash Bhatta Department of Emergency Medicine, Nova Hospital, Nepal Sabita Chand Department of Emergency Medicine, Nova Hospital, Nepal Neha Dangol Department of Emergency Medicine, Nova Hospital, Nepal Sachin Awasthi Department of Emergency Medicine, Yashoda Hospital, Nepal Ram Chandra Poudel Department of Internal Medicine, Nova Hospital, Nepal Ram Prasad Lamichhane Department of Psychiatry, Nova Hospital, Nepal
dc.description.abstractAbstract Crigler–Najjar Syndrome Type 2 (CNS2) is a rare autosomal recessive disorder characterized by unconjugated hyperbilirubinemia due to partial deficiency of the enzyme uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). We present a case of a 13-month-old male admitted to Kanti Children’s Hospital with persistent jaundice since birth. Diagnostic evaluation accompanied by gene sequencing confirmed CNS2 and the patient was effectively managed with orally administered phenobarbitone. CNS2 can be distinguished from other potential causes of unconjugated hyperbilirubinemia based on bilirubin concentration and the affected patient’s response to phenobarbitone. Genetic counselling is essential for the recognition and prevention of severe hyperbilirubinemia which, in the absence of timely medical intervention, may lead to neurotoxicity. Keywords: Case report; crigler-Najjar syndrome; genetic counseling; phenobarbitone; unconjugated hyperbilirubinemia.
dc.identifierhttps://doi.org/10.33314/jnhrc.v23i01.4908
dc.identifier.urihttps://hdl.handle.net/20.500.14572/140
dc.language.isoen_US
dc.publisherNepal Health Research Council
dc.titleTapentadol withdrawal, a newer trend in opioid overuse in Nepal: A case report
dc.typeArticle
dspace.entity.typePublication
local.article.typeCase Report
oaire.citation.endPage207
oaire.citation.startPage205
relation.isJournalIssueOfPublication3fed4900-8521-418d-9665-3879c2fd5ea1
relation.isJournalIssueOfPublication.latestForDiscovery3fed4900-8521-418d-9665-3879c2fd5ea1
relation.isJournalOfPublicationa782b7ff-cf89-4178-ad1c-11ed89cfe1bd

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
webmaster,+Jan_Mar_2025+Issue-4-218-205-207.pdf
Size:
705.03 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.86 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Publications

Connect with us

Nepal Health Research Council © 2023
Ramshah Path, Kathmandu Nepal P.O.Box 7626